We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

RNA Reference Materials Useful for Standardizing COVID-19 Tests, Finds Study

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Illustration
Illustration

A new study has shown that RNA reference materials are useful for standardizing COVID-19 tests.

The multiorganizational study led by researchers at the National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) looked at anchoring cycle threshold (Ct) values to a reference sample with known amounts of the virus in an effort to make the COVID-19 tests results more comparable between labs.

Scientists track and monitor the circulation of SARS-CoV-2, the virus that causes COVID-19, using methods based on a laboratory technique called polymerase chain reaction (PCR). Also used as the “gold standard” test to diagnose COVID-19 in individuals, PCR amplifies pieces of DNA by copying them numerous times through a series of chemical reactions. The number of cycles it takes to amplify DNA sequences of interest so that they are detectable by the PCR machine, known as Ct, is what researchers and medical professionals look at to detect the virus. However, not all labs get the same Ct values.

SARS-CoV-2 is an RNA virus: Its genetic material is single-stranded instead of double-stranded like DNA and contains some different molecular building blocks, namely uracil in place of thymine. But the PCR test only works with DNA, and labs first must convert the RNA to DNA to screen for COVID-19. For the test, RNA is isolated from a patient’s sample and combined with other ingredients, including short DNA sequences known as primers, to transform the RNA into DNA. When running a PCR test, labs often use the Ct value to make a positive or negative diagnosis of COVID-19. Labs often set a “cutoff” Ct value above which they interpret and can declare a patient “negative” if the virus is not detected after a certain number of cycles. But even though different labs can accurately detect the virus using their PCR tests, they use their own test methods and instruments, which could lead to different Ct values.

So, for this study, a multiorganizational research team set out to explore how much Ct values could vary among different labs when they ran PCR tests on the same reference samples containing known amounts of the SARS-CoV-2 virus. Two reference materials with carefully measured concentrations of the SARS-CoV-2 RNA were developed by a group of organizations and institutions. RM 1 had an estimated viral load of 10 million (107) copies per milliliter, and RM 2 had an estimated viral load of one million (106) copies per milliliter.

To ensure these values were accurate, metrology institutes measured and validated the reference materials using digital PCR. Digital PCR follows the same steps as traditional PCR but is a more advanced version. In digital PCR, the sample is partitioned into thousands of tiny droplets. A compound is also added so when the targeted DNA is detected it gives off a glow, allowing researchers to confirm if the sample is positive for the coronavirus with the presence of the fluorescent molecules.

The reference materials were sent out to a total of 305 laboratories in Germany, which yielded 1,109 data sets to be analyzed. The Ct values differed between labs depending on the test system or PCR equipment used and the targeted DNA sequences of the virus. For example, PCR assays aiming to detect a key gene (the “N” gene) in the COVID-19 virus had a range of Ct values between 17.6 and 26.9 for RM 1, while for RM 2 the range was between 20.7 and 30.1. The ranges between the two RMs overlap (20.7 to 26.9) even though they have different viral load concentrations, which shows it’s not possible to tell the precise concentration from Ct values alone.

The differences in Ct values among labs showed the usefulness of reference materials as a tool to help labs compare and standardize their results. Some have previously viewed the Ct value as a way to measure the viral load, the amount of virus in a person’s body. But the variation in Ct values across labs underscores that the two variables are merely correlated with one another. For example, if an individual has a higher viral load, then their Ct value would be low because it would take fewer cycles to amplify the virus’s genetic material. However, by using the appropriate reference materials, Ct values can potentially be converted to an actual virus concentration value in copies per microliter, which would be one way to quantify the viral load, though this wasn’t a focus of the study

Some have also suggested using Ct values to determine how infectious a patient is, another practice that the researchers caution against. Even though Ct values alone don’t determine how sick or infected an individual is, understanding these values could help inform decisions on setting criteria for monitoring people affected by the coronavirus. And RNA reference materials can help make these results more reliable and comparable.

“A lower Ct value means more DNA with the coronavirus starting out in the sample. It correlates to the viral load. But Ct can vary depending on the extraction material or the method used. All of these things can affect at which point the DNA is detected,” said NIST researcher Megan Cleveland, a co-author of the study. “People should use well-characterized reference materials along with their test methods instead of just relying on the Ct values. On its own, the Ct values are not easily comparable between testing laboratories, but researchers having access to reference materials and understanding their importance is beneficial.”

Related Links:
NIST

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.